Om

PCI Biotech Holding ASA is a biopharmaceutical company headquartered in Oslo, Norway, focused on developing innovative cancer therapies and drug delivery technologies via its proprietary photochemical internalization (PCI) platform. This technology, derived from research at Oslo University Hospital, uses light to trigger the release of therapeutic compounds from cellular endosomes, enhancing their effectiveness across various modalities. The company advances three key programs: fimaCHEM to boost chemotherapeutic drugs for localized cancer treatments; fimaVACC to stimulate T-cell responses in cancer vaccination and intratumoural immunotherapy; and fimaNAC for nucleic acid therapeutics targeting dermatological conditions like chronic skin ulcers and bioprocessing applications such as viral vector manufacturing via photochemical lysis (PCL). Its lead product candidate, fimaporfin (Amphinex), acts as a photosensitizer to overcome intracellular barriers. With a lean team of approximately seven employees led by CEO Ronny Skuggedal, PCI Biotech emphasizes preclinical research and partnership-driven strategies in the biotechnology sector, contributing to advancements in light-activated therapies for oncology and beyond.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I PCI BIOTECH HOLDING MED ENDAVU: Køb PCI Biotech Holding ($4QG) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i PCI Biotech Holding, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.